Puma Reports Positive Interim PB272 Phase II Data, Showws Efficacy in Combo with Temsirolimus in HER2+ Breast Cancer
December 12, 2014 at 09:06 AM EST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that interim results from an ongoing ...
